Latest

27 Mar'26 Portfolio

Finding plenty of opportunities despite weak market indices

CrowdStrike And The AI Agents Cyber Threat (Archive)

AI agents erode CrowdStrike’s moat as growth, valuation and technicals all turn bearish.

Otsuka Holdings: New FDA‑Backed Kidney Drug Could Ignite a Multi‑Year Rally

FDA-backed kidney breakthrough and ADHD catalyst support Otsuka’s breakout despite looming patent cliffs.

Micron Says Go Big Or Go Home As It Ramps Up Capex Far More Than Peers (Archive, Full Access)

Micron’s AI memory bonanza is compelling, but aggressive capex keeps the rating at Hold.

Palantir: This Selloff Is A Gift (Archive, Full Access)

Palantir’s Maven AI win, hiring surge, and scalable ontology make this PLTR pullback compelling.

Dell: Why It's Not A Buy Despite A $43 Billion AI Backlog (Archive, Full Access)

Explosive AI demand meets fair valuation and looming PC and margin headwinds.

A Canadian Natural Gas Giant Winning From Global LNG Disruptions

Global LNG disruptions could drive a multi‑year free‑cash‑flow surge for this producer.